NEW YORK (GenomeWeb News) – Molecular diagnostics company Prolias Technologies today announced it has licensed intellectual property covering microRNA-based diagnostics from Cornell University.

The technologies were developed at the Weill Cornell Medical College. The first series of IP includes a panel called Thymira that differentiates malignant from benign indeterminate thyroid nodules. Prolias, which said it anticipates commercially launching the panel in the coming months, also has licensed an algorithm to interpret results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.